Chest Medicine (all articles)
‘Real world’ study by CDC shows Pfizer and Moderna vaccines were 90% effective
30 Mar, 2021 | 03:27h | UTC‘Real world’ study by CDC shows Pfizer and Moderna vaccines were 90% effective – STAT
Commentary on Twitter (thread – Click for more)
Prospective study in the US finds mRNA vaccine efficacy against SARS-CoV-2 infection (symptomatic or not) of 90% (CI: 68–97) after 2 doses, & 80% (CI: 59–90) after 1 dose. (Wide CI because few people got infected)…1/2 https://t.co/RSf3xFtL29 HT @HelenBranswell
— Hilda Bastian, PhD (@hildabast) March 29, 2021
COVID-19, Personal Protective Equipment, and Human Performance
30 Mar, 2021 | 03:14h | UTCCOVID-19, Personal Protective Equipment, and Human Performance – Anesthesiology
Study: mRNA vaccine is associated with decreased SARS-CoV-2 viral load in individuals with breakthrough infection, suggesting a role in suppressing onward transmission
30 Mar, 2021 | 03:25h | UTC
Commentaries on Twitter
A study in @NatureMedicine reports that breakthrough SARS-CoV-2 infections occurring 12 or more days after the first dose of the Pfizer-BioNTech vaccine had lower viral loads, suggesting the vaccine might reduce infectiousness. https://t.co/yskN9lgiwr pic.twitter.com/LQVESgRjZz
— Nature Research (@nresearchnews) March 29, 2021
(Thread – Click for more)
New @NatureMedicine: The concern about asymptomatic transmission addressed in nearly 5,000 people after 1st dose of mRNA vaccine (~2 -5 wks). Viral load markedly reduced (high Ct). Supports vaccine effect for blocking or strongly reducing chance of spreadhttps://t.co/mmJmZPZfHK pic.twitter.com/0TTf4cFZed
— Eric Topol (@EricTopol) March 29, 2021
COVID associated with hearing loss, tinnitus and vertigo – new study confirms link
30 Mar, 2021 | 03:19h | UTCOriginal study: One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms – International Journal of Audiology
Cochrane Library Editorial: Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID‐19
28 Mar, 2021 | 22:55h | UTCCommentary and Infographic: Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus? – Cochrane Library
Original review: Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19 – Cochrane Library
Commentary on Twitter
New #VisualAbstract for the @Cochrane_IDG systematic review on #Chloroquine or #hydroxychloroquine for prevention and treatment of #COVID19 https://t.co/U7TnMzQTil Many thanks to @tylerdau & @cg_coleman from @EmoryMedicine pic.twitter.com/tlFKKa31E8
— The Cochrane Library (@CochraneLibrary) March 25, 2021
Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies
30 Mar, 2021 | 03:12h | UTC
Commentary on Twitter
Proud to present our meta-analysis of a highly-debated topic! The synthesized evidence of almost 9000 critically ill patients with #COVID_19 suggests that #early_intubation, as suggested by several #guidelines, may not be justified. @crit_care
?https://t.co/eClJlHhYDp pic.twitter.com/DVIop0yGmM
— Vassilis Giannakoulis (@VGiannakoulis) March 27, 2021
RCT: Discontinuing betalactam treatment after 3 days as good as 8 days of treatment for stable patients with community-acquired pneumonia in non-critical care wards
28 Mar, 2021 | 22:25h | UTC
Commentary on Twitter
Less can be more for pneumonia. In 50% CAP patients was possible stop Abx at 3 days and outcomes were the same @TheLancet https://t.co/Hc1AxyndWS pic.twitter.com/Ypk2uXeDQV
— Michael Marks (@dr_michaelmarks) March 26, 2021
Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination
28 Mar, 2021 | 22:53h | UTC
Commentaries on Twitter
Now a peer-reviewed pub in a top journal, this elegant study clearly shows that variant B.1.351 isn't stopped by antibodies from prior infection or the Pfizer vax. We'll have revised vaccines, but we don't yet. Please behave accordingly. https://t.co/w8GHPDB7aL
— EQV Analytics (@AnalyticsEqv) March 27, 2021
New @NatureMedicine, further data on immune response after vaccination to 2 variants, B.1.1.7 (UK) and B.1.351 (SA). Reinforcing recent reports, the latter is more of an immune evader, and may pose vulnerability for reinfection post-vaccinehttps://t.co/w8xFc3fkh5 pic.twitter.com/i7DAnjSZwE
— Eric Topol (@EricTopol) March 26, 2021
Covid-19: Middle aged women face greater risk of debilitating long term symptoms
28 Mar, 2021 | 22:49h | UTCCovid-19: Middle aged women face greater risk of debilitating long term symptoms – The BMJ
Linked Opinion: The stigma is real for people living with long covid – The BMJ Opinion
How COVID-19 Affects the Brain
28 Mar, 2021 | 22:51h | UTCHow COVID-19 Affects the Brain – JAMA Psychiatry
Commentary on Twitter
#COVID19 brain symptoms are a rising concern. Mechanisms of brain damage by the virus include lasting neuroinflammation, thrombotic events and alteration of neurotransmitters release. Consequently, people suffer cognitive, emotional and behavioral symptoms https://t.co/pTzJo6DLV8
— JAMA Psychiatry (@JAMAPsych) March 26, 2021
Opinion | The Coronavirus Variants Don’t Seem to Be Highly Variable So Far
28 Mar, 2021 | 22:46h | UTCThe Coronavirus Variants Don’t Seem to Be Highly Variable So Far – Scientific American
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”
28 Mar, 2021 | 22:48h | UTCCommentary: 85% of COVID-19 long-haulers have multiple brain-related symptoms – LiveScience AND ‘Brain fog’ and other neurologic symptoms can last for months after Covid – NBC News AND Neurologic Symptoms Persistent for Many COVID-19 ‘Long-Haulers’ – Health Day
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
28 Mar, 2021 | 22:40h | UTCInterleukin‐6 blocking agents for treating COVID‐19: a living systematic review – Cochrane Library
Commentary on Twitter
JUST PUBLISHED – Interleukin‐6 blocking agents for treating #COVID19 https://t.co/pt8BNfBwa3 New living systematic review from @Cochrane_ACE looks at the evidence from 10 studies in 6896 people with COVID‐19 pic.twitter.com/hjs97lPBEt
— Cochrane UK (@CochraneUK) March 26, 2021
Opinion | COVID-19 Is Different Now: The coronavirus is changing. So is the disease it causes.
28 Mar, 2021 | 22:44h | UTCCOVID-19 Is Different Now – The Atlantic
Pushing back against U.S. health officials, AstraZeneca says new analysis confirms efficacy of its Covid-19 vaccine
26 Mar, 2021 | 09:01h | UTCNews release: AZD1222 US Phase III primary analysis confirms safety and efficacy – AstraZeneca
See also: Latest results put Oxford–AstraZeneca COVID vaccine back on track – Nature AND AstraZeneca’s absurd and unprecedented dispute with regulators, explained – Vox AND Expert reaction to press release from AstraZeneca announcing primary data on safety and efficacy from the US trial of the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca says COVID-19 vaccine 76% effective in new analysis, to seek U.S. approval – Reuters AND AstraZeneca’s new data showing Covid vaccine slightly less effective than suggested doesn’t worry experts – The Guardian AND Latest AstraZeneca Report Supports Effectiveness Of COVID Vaccine – NPR
Practice Pointer: Remote management of Covid-19 using home pulse oximetry and virtual ward support
26 Mar, 2021 | 09:05h | UTCRemote management of covid-19 using home pulse oximetry and virtual ward support – The BMJ
Related: Virtual clinics are reassuring but sometimes daunting – The BMJ
Commentary on Twitter
Our new BMJ paper – home oximetry and virtual wards (how to do it, when to do it, tips and caveats). @drmknight @mattinadakim @CeciliaVindrola Naomi Fulop @jonathanleach13 https://t.co/AOUIztHHwx
— Trisha Greenhalgh ? #CovidIsAirborne (@trishgreenhalgh) March 25, 2021
RCT: Similar number of days free of respiratory support with helmet noninvasive ventilation vs. high-flow nasal oxygen in patients with COVID-19 and moderate to severe hypoxemic respiratory failure
26 Mar, 2021 | 09:02h | UTCEffect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Respiratory Support During the COVID-19 Pandemic: Is It Time to Consider Using a Helmet?
Video: Helmet Noninvasive Ventilation of COVID-19 Patients
Another study shows increased transmissibility of SARS-CoV-2 lineage B.1.1.7 with a 50% to 100% higher reproduction number
26 Mar, 2021 | 08:57h | UTCAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England – Nature
Related: Study confirms higher transmissibility of SARS-CoV-2 lineage B.1.1.7 (study and commentary)
Commentary on Twitter
Just published @nature: Transmissibility of the B.1.1.7 (UK) variant https://t.co/dsMge8bB83 "A substantial transmission advantage with a 50 to 100% higher reproduction number"
Secondary attack rates were 30-40% higher than ancestral strain (non-VOC); no age gradient by modeling pic.twitter.com/870A3PojyF— Eric Topol (@EricTopol) March 25, 2021
Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)
26 Mar, 2021 | 08:53h | UTCCovid: The London bus trip that saved maybe a million lives – BBC
Related: Covid-19: The Inside Story of the RECOVERY Trial
Commentary on Twitter
Very cool story by @JamesTGallagher about a convo on a London bus that led to the creation of the RECOVERY trial, which has been a shining (& too rare) example of how to do critical research in a pandemic. Bravo @PeterHorby & @MartinLandray h/t @hildabast https://t.co/BRSJLSFXdc
— Helen Branswell (@HelenBranswell) March 25, 2021
[Press release – not published yet] Trial of multi drug-resistant TB treatment ends enrolment early after independent board indicates new regimen is superior
25 Mar, 2021 | 08:10h | UTC
Commentary on Twitter
Promising news improving treatment #MDR #TB https://t.co/Lxjb7LBofy Translating findings to available drugs & diagnostics back it up will be key pic.twitter.com/YGp8d9ixww
— Michael Marks (@dr_michaelmarks) March 24, 2021
WHO Campaign | World Tuberculosis Day 2021: The Clock Is Ticking
24 Mar, 2021 | 08:16h | UTCWorld Tuberculosis Day 2021: The Clock Is Ticking – World Health Organization
Perspective | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
25 Mar, 2021 | 08:34h | UTC
Systematic review: Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection
25 Mar, 2021 | 08:38h | UTCCommentaries: Updated Cochrane review assesses how accurate rapid tests are for detecting COVID-19 – Wiley AND Expert reaction to updated Cochrane review of studies on accuracy of rapid tests (including lateral flow and molecular tests) to detect SARS-CoV-2 – Science Media Centre
NICE publishes single guideline for managing COVID-19
24 Mar, 2021 | 08:42h | UTCNews release: COVID-19 rapid guideline: managing COVID-19 – National Institute for Health and Care Excellence
Commentary on Twitter
Today NICE has published a single guideline for managing COVID-19, which brings together content from previous rapid COVID-19 guidance and evidence summaries. Read more: https://t.co/3O5yzpHK9e pic.twitter.com/DyD7lcLX8v
— NICE (@NICEComms) March 23, 2021
WHO Guideline: Screening for Tuberculosis Disease
24 Mar, 2021 | 08:13h | UTCSee also: WHO Operational Handbook on Systematic Screening for Tuberculosis – World Health Organization